Home » BARR PROFITS CLEAR ESTIMATES
BARR PROFITS CLEAR ESTIMATES
arr Pharmaceuticals said strong sales of generic products and the performance
of drug pacts with Teva (TEVA:Nasdaq ADR commentary research
Cramer's Take) and Kos Pharmaceuticals (KOSP:Nasdaq commentary - research
Cramer's Take) helped lift fiscal first-quarter revenue 27% from a year
ago. The Woodcliff Lake, N.J., drug company earned $83.2 million, or 78 cents
a share, on revenue of $310 million for the quarter ended Sept. 30. A year ago,
Barr earned $52.1 million, or 49 cents a share, and had revenue of $245 million.
The
Street
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May